US · ABEO
Abeona Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cleveland, NY 10019
- Website
- abeonatherapeutics.com
Price · as of 2024-12-31
$5.43
Market cap 277.46M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.00 | +415.65% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $2,500.00 | $73,805.07 | $9,373.30 | $0.00 | $0.00 |
| 2011 | $1,437.50 | $136,406.49 | $1,769,762.56 | $0.00 | $0.00 |
| 2012 | $575.00 | $118,340.73 | $181,075,616.49 | $0.00 | $0.00 |
| 2013 | $462.50 | $60,271.62 | $2,359,232.74 | $369.71 | $0.00 |
| 2014 | $85.00 | $102,011,544.40 | $173.19 | $0.00 | $61,038.45 |
| 2015 | $69.75 | $247.37 | $45.46 | $0.00 | $0.00 |
| 2016 | $127.50 | $76.31 | $52.36 | $0.00 | $93.36 |
| 2017 | $382.50 | $167.25 | $81.39 | $0.62 | $0.00 |
| 2018 | $179.25 | $121.19 | $52.26 | $0.00 | $0.00 |
| 2019 | $68.00 | $27.20 | |||
| 2020 | $58.75 | $11.00 | $0.00 | ||
| 2021 | $7.00 | $11.14 | $0.00 | $0.00 | $1,268.78 |
| 2022 | $2.69 | $29.09 | $0.00 | $0.00 | $213.95 |
| 2023 | $7.97 | $35.24 | $0.01 | $0.00 | $0.00 |
| 2024 | $5.16 | $28.00 |
AI valuation
Our deep-learning model estimates Abeona Therapeutics Inc.'s (ABEO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.00
- Current price
- $5.43
- AI upside
- +415.65%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ABEO | Abeona Therapeutics Inc. | $5.43 | 277.46M | +416% | — | — | — | -3.32 | 4.81 | — | -2.42 | — | 4.81 | 0.00% | — | — | -216.57% | 205.01% | -73.71% | 0.52 | -15.26 | 6.08 | 5.99 | 0.01 | -3874.00% | -10000.00% | 5656.00% | -27.60% | -3.38 | 186.65% | 0.00% | 0.00% | 0.00% | -2.14 | -2.35 | — | -9.51 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| ASMB | Assembly Biosciences, Inc… | $29.84 | 256.95M | +2,630% | +9,923% | — | — | -1.66 | 2.00 | 2.34 | 0.93 | — | 2.00 | 100.00% | -159.26% | -140.87% | -107.92% | 55.92% | -31.39% | 0.09 | — | 2.42 | 2.35 | 0.78 | -5000.00% | 29816.00% | -32743.00% | -76.60% | -1.07 | 62.97% | 0.00% | 0.00% | 26.59% | 0.93 | 0.83 | -1.48 | -9.57 |
| ELDN | Eledon Pharmaceuticals, I… | $2.62 | 157.07M | — | — | — | — | -5.08 | 1.56 | — | -1.26 | — | 2.15 | 0.00% | — | — | -57.73% | 218.52% | -27.16% | 0.01 | — | 12.42 | 12.11 | 0.55 | -5427.00% | — | 1959.00% | -25.69% | -4.08 | 146.36% | 0.00% | 0.00% | 8.35% | -0.63 | -0.95 | — | -1.36 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| PBYI | Puma Biotechnology, Inc. | $5.70 | 287.23M | +433% | +114% | 0% | -22% | 10.32 | 2.46 | 1.41 | 4.73 | — | 3.61 | 74.53% | 16.33% | 13.62% | 27.97% | 51.23% | 14.48% | 0.22 | 5.63 | 2.00 | 1.86 | -0.02 | -161.00% | -91.00% | 738.00% | 13.00% | 0.51 | 65.93% | 0.00% | 0.00% | 1.85% | 6.76 | 6.04 | 1.10 | -3.99 |
| SGMT | Sagimet Biosciences Inc. | $5.71 | 177.02M | +358% | — | — | — | -2.53 | 0.74 | — | 0.79 | — | 0.74 | 0.00% | — | — | -36.92% | -12575.98% | -35.46% | 0.00 | — | 34.30 | 33.96 | 1.66 | -523.00% | -10000.00% | 7855.00% | -36.78% | -9.53 | -9800.23% | 0.00% | 0.00% | 0.60% | 0.66 | 0.84 | — | 12.95 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
- CEO
- Vishwas Seshadri
- Employees
- 136
- Beta
- 1.13
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.43) − 1 = — (DCF, example).